NASDAQ: CUE
Cue Biopharma Inc Stock Ownership - Who owns Cue Biopharma?

Insider buying vs selling

Have Cue Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Daniel R. PasseriCHIEF EXECUTIVE OFFICER2024-12-1630,000$1.03
$30.90kBuy

1 of 1

CUE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CUE insiders and whales buy or sell their stock.

CUE Shareholders

What type of owners hold Cue Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bleichroeder LP6.63%4,997,240$3.91MInstitution
Vanguard Group Inc3.07%2,315,862$1.81MInstitution
Cameron Gray1.70%1,283,249$1.00MInsider
Aaron Gl Fletcher1.48%1,113,867$872.16kInsider
Michael J. Fox1.46%1,100,000$861.30kInsider
Christopher A. Marlett1.02%768,503$601.74kInsider
Geode Capital Management LLC0.92%693,890$543.32kInstitution
Blackrock Inc0.84%635,203$497.36kInstitution
Robertson Stephens Wealth Management LLC0.64%478,500$374.67kInstitution
Ronald D. Seidel Iii0.59%445,000$348.44kInsider

1 of 3

CUE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CUE15.13%7.51%Net Buying
CNTX79.60%1.46%Net BuyingNet Buying
SNTI18.72%81.28%Net Buying
PDSB18.00%25.86%Net Buying
IFRX25.86%0.00%

Cue Biopharma Stock Ownership FAQ

Who owns Cue Biopharma?

Cue Biopharma (NASDAQ: CUE) is owned by 15.13% institutional shareholders, 7.51% Cue Biopharma insiders, and 77.36% retail investors. Cameron Gray is the largest individual Cue Biopharma shareholder, owning 1.28M shares representing 1.70% of the company. Cameron Gray's Cue Biopharma shares are currently valued at $1.02M.

If you're new to stock investing, here's how to buy Cue Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.